A detailed history of Caxton Associates LLP transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Caxton Associates LLP holds 17,356 shares of DVAX stock, worth $165,055. This represents 0.01% of its overall portfolio holdings.

Number of Shares
17,356
Holding current value
$165,055
% of portfolio
0.01%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 15, 2025

BUY
$12.39 - $14.4 $215,040 - $249,926
17,356 New
17,356 $225 Million

Others Institutions Holding DVAX

About DYNAVAX TECHNOLOGIES CORP


  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.2B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track This Portfolio

Track Caxton Associates LLP Portfolio

Follow Caxton Associates LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caxton Associates LLP, based on Form 13F filings with the SEC.

News

Stay updated on Caxton Associates LLP with notifications on news.